Secondary Logo

Institutional members access full text with Ovid®

Candida krusei Emphysematous Pyelonephritis Possibly Due to Dapagliflozin Therapy

Fox, Lanae, PharmD, BCPS*†; Nelson, A. Christie, PharmD, BCPS; Ghanem, Ghazi, MD

Infectious Diseases in Clinical Practice: November 2018 - Volume 26 - Issue 6 - p 363–365
doi: 10.1097/IPC.0000000000000588
Case Reports

Dapagliflozin is a new oral antidiabetic medication from the sodium glucose cotransporter-2 inhibitor class. Sodium glucose cotransporter-2 inhibitors work by preventing reabsorption of glucose in the kidney, thereby wasting it through urine. This unique mechanism increases the risk of urinary tract infections and genital mycotic infections. We present a rare case of fungal emphysematous pyelonephritis in a patient on dapagliflozin.

From the *University of Wyoming School of Pharmacy, Laramie;

Wyoming Medical Center;

Rocky Mountain Infectious Diseases, Casper, WY.

Correspondence to: Lanae Fox, PharmD, BCPS, University of Wyoming School of Pharmacy, Laramie, WY 82071; Wyoming Medical Center, 1233 E. A St, Casper, WY 82601. E-mail:

The authors have no funding or conflicts of interest to disclose.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.